This is really fascinatin medical analysis. The question about why Biden chose 4-5 weeks of conventional RT instead of SBRT is pretty puzzling given that the shorter course would be less disruptive and has comparable outcomes. Maybe there's something about his specific case that made the longer course preferable, or maybe it just came down to where he was getting treated and what they offered. The transdermal estrogen point is really compeling though, especially for an 82-year-old dealing with metastatic disease. Quality of life should be paramount at that stage, and if tE2 can provide equivalent cancer control while reducing the harsh side effects of conventional ADT, it seems like a no-brainer. The cardiovascular risk elimination via transdermal vs oral delivery is a huge deal. The FDA approval barrier you mention is frustrating because it's such a clear example of how regulatory structures can lag behind medical knowledg. Men and women aren't that different when it comes to hormone delivery systems, this should be a solvable problem.
Outtah the park, Howard! I have to say though, anytime I see 'surgical castration' it freaks me out. This work by Dr. Schellhammer is so cutting edge it could do the surgery (sorry, bad pun). It looks like we are FINALLY getting some attention on the real issue, hormones. Just pathetic that the mentality is "Oh, he has PCa, let's cut his balls off." Then big pharma found a way to capitalize on the whole thing by throwing a colossal kinase monkey-wrench into what is an extremely sophisticated control system that does not age well (the designer saw no need after child-siring years were over).
What killed me was the statement: "The products currently available for the transdermal delivery of E2 are FDA-approved only for use in women." and it underscores the very sad fact that medicine, especially US medicine, has seemed to forget that we are the SAME SPECIES--things are configured differently between the genders and the control parameters have different settings, but at the end of the day we are fundamentally the same.
While the behemoth's battle it out, there are natural ways (supps) to modify hormonal balance.
Thanks, Harley. I have been focused on articles on AS. But the response to this story indicates I should include more stories about patients with more advanced cancers.
Howard, thanks for this article that is very important for me today because my PSA has increased from 8 to 10.5 in the past 6 months after staying on AS for 3 years (2022-2025) when PSA has been in the range of 6-8. So, my local urologist recommends to apply for the consultation with some Moscow's oncourologist for a new MRI scan and probably the ADT treatment. The details in my personal email.
I hope tE2 eventually becomes easliy obtainable OTC for tiny cost in the US as it is in Mexico, GB, the EU, the middle and far east. But the lobbyists for the manufacturers of Lupron will be whining to the Congressmen that if they allow tE2 to be sold easily to anyone who wants it, the Congressmen's donations to those pols will get smaller and alot of urologists will need to downsize the vehicle they drive. Congress cannot allow the HT biz to be unprotected from foreigners selling a natural product too inexpensively just because its worked for estrogen surpression around the world for more than seventy-five years. They must protect the tribe.
This is really fascinatin medical analysis. The question about why Biden chose 4-5 weeks of conventional RT instead of SBRT is pretty puzzling given that the shorter course would be less disruptive and has comparable outcomes. Maybe there's something about his specific case that made the longer course preferable, or maybe it just came down to where he was getting treated and what they offered. The transdermal estrogen point is really compeling though, especially for an 82-year-old dealing with metastatic disease. Quality of life should be paramount at that stage, and if tE2 can provide equivalent cancer control while reducing the harsh side effects of conventional ADT, it seems like a no-brainer. The cardiovascular risk elimination via transdermal vs oral delivery is a huge deal. The FDA approval barrier you mention is frustrating because it's such a clear example of how regulatory structures can lag behind medical knowledg. Men and women aren't that different when it comes to hormone delivery systems, this should be a solvable problem.
Outtah the park, Howard! I have to say though, anytime I see 'surgical castration' it freaks me out. This work by Dr. Schellhammer is so cutting edge it could do the surgery (sorry, bad pun). It looks like we are FINALLY getting some attention on the real issue, hormones. Just pathetic that the mentality is "Oh, he has PCa, let's cut his balls off." Then big pharma found a way to capitalize on the whole thing by throwing a colossal kinase monkey-wrench into what is an extremely sophisticated control system that does not age well (the designer saw no need after child-siring years were over).
What killed me was the statement: "The products currently available for the transdermal delivery of E2 are FDA-approved only for use in women." and it underscores the very sad fact that medicine, especially US medicine, has seemed to forget that we are the SAME SPECIES--things are configured differently between the genders and the control parameters have different settings, but at the end of the day we are fundamentally the same.
While the behemoth's battle it out, there are natural ways (supps) to modify hormonal balance.
Thanks, Harley. I have been focused on articles on AS. But the response to this story indicates I should include more stories about patients with more advanced cancers.
Howard
Indeed. Hard to separate them and now that many AS patients are into 10 years+ on, the old dragon is waking and rearing it's ugly head.
Howard, thanks for this article that is very important for me today because my PSA has increased from 8 to 10.5 in the past 6 months after staying on AS for 3 years (2022-2025) when PSA has been in the range of 6-8. So, my local urologist recommends to apply for the consultation with some Moscow's oncourologist for a new MRI scan and probably the ADT treatment. The details in my personal email.
I hope tE2 eventually becomes easliy obtainable OTC for tiny cost in the US as it is in Mexico, GB, the EU, the middle and far east. But the lobbyists for the manufacturers of Lupron will be whining to the Congressmen that if they allow tE2 to be sold easily to anyone who wants it, the Congressmen's donations to those pols will get smaller and alot of urologists will need to downsize the vehicle they drive. Congress cannot allow the HT biz to be unprotected from foreigners selling a natural product too inexpensively just because its worked for estrogen surpression around the world for more than seventy-five years. They must protect the tribe.